Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2023-02-21 Capital/Financing Update
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
주요사항보고서(교환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the issuance of exchangeable bonds (교환사채권 발행결정). This document details the terms of the financing, including interest rates, maturity, exchange prices, and the use of proceeds. As it pertains to company fundraising and capital structure changes, it falls under the 'Capital/Financing Update' category.
2023-02-21 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange). It specifically details a 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). According to the provided definitions, the category 'Transaction in Own Shares' (POS) is the correct classification for reports regarding a company buying back or selling its own shares.
2023-02-21 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This document details the company's plan to sell or distribute its own shares. According to the provided definitions, the category 'Transaction in Own Shares' (POS) specifically covers reports of the company buying back or selling its own shares.
2023-02-21 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Clinomics. It outlines the date, location, and agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2023-02-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Clinomics) announcing a significant change in revenue or profit structure (30% or more). This is a standard disclosure requirement for listed companies in Korea to report preliminary financial results before the final audit is completed. Since it provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the change, it fits the definition of an Earnings Release (ER). FY 2022
2023-02-17 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details changes in share ownership by Amicogen, Inc. and its special related party (Shin Yong-chul) in Clinomics Co., Ltd. This type of filing is specifically designed to notify the market when a shareholder's stake crosses certain thresholds or changes significantly, which corresponds to the 'Major Shareholding Notification' category.
2023-02-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.